ClinicalTrials.gg

Program

TQA3810

A development code. Also written as “TQA3810 tablets+NUC”.

In Sino Biopharmaceutical's pipeline, TLR-8激动剂. Its studies are mostly in Hepatitis B, Chronic, led by Sino Biopharmaceutical.

Furthest: phase 2, since Aug 20, 20242 company-led studies, 1 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical21 open or runningphase 2since Aug 20, 2024May 21, 2024none ahead
  • Named in Sino Biopharmaceutical’s own pipeline as TQA3810, phase 2, as of Nov 16, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 21, 2024First study: phase 1 study in Hepatitis B, ChronicFirst studyNCT06431438 · 759 enrolled · China
  2. Aug 20, 2024Phase 2 study in Hepatitis B, ChronicNCT06566248 · 90 planned · China

TargetBeta

“TLR-8激动剂”the company's pipeline, read by Claude · source

Other programs on TLR8

ProgramCompanyFurthest phaseStudies
resiquimodruleStaidson (Beijing) Biopharmaceuticalsphase 314
enpatoranruleMerck KGaA, Darmstadt, Germanyphase 312
afimetoranruleBristol-Myers Squibbphase 312

Studies

All 2 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06566248Hepatitis B, Chronic · China2RecruitingSep 202490
NCT06431438Hepatitis B, Chronic · China1CompletedNov 20, 2023759

How it is read

Names in the registry

  • “TQA3810 tablets+NUC”, 1 entry
  • “TQA3810”, 1 entry

Codes read as this program: TQA3810.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.